Identification of small molecules that inhibit GSK-3beta through virtual screening

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Glycogen synthase kinase-3beta (GSK-3beta) plays a crucial role in cellular processes including metabolism and development.
• GSK-3beta inhibitors are being explored for treating conditions such as type II diabetes, bipolar disorder, stroke, and inflammatory diseases.

Purpose of the Study:

• To identify novel small molecule inhibitors of GSK-3beta with unique chemical structures.
• To evaluate the potency and selectivity of identified inhibitors against GSK-3beta.

Main Methods:

• Utilized computer modeling for initial screening of potential GSK-3beta inhibitors from a chemical library.
• Employed in vitro Z'-LYTE assay to assess the inhibitory activity of selected compounds.
• Determined enzyme kinetics using the Lineweaver-Burk equation to understand the inhibition mechanism.
• Assessed selectivity against other kinases.

Main Results:

• A series of compounds, designated KRMs, demonstrated potent inhibition of GSK-3beta phosphorylation with IC50 values around 0.5 μM.
• Compounds KRM-189 and KRM-191 were found to compete with ATP binding, decreasing Vmax and maintaining Km.
• These inhibitors exhibited selectivity for GSK-3beta over other kinases, with IC50 values of 2–10 μM or higher.
• KRM-191 treatment led to beta-catenin accumulation in cells, confirming GSK-3beta pathway inhibition.

Conclusions:

• Computer modeling combined with in vitro assays is an effective strategy for discovering selective and potent GSK-3beta inhibitors.
• The identified KRM compounds, particularly KRM-191, represent promising candidates for further therapeutic development targeting GSK-3beta.